{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:44:23Z","timestamp":1791866663744,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus reactivation (CMVR) after allogeneic hematopoietic cell transplantation (allo\u2010HCT) is a reversible event, and conventional indicators such as the simple cumulative incidence cannot reflect transitional CMVR states. We propose a novel indicator, current CMVR (cCMVR), which visualizes both the occurrence and remission of CMVR over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To evaluate the utility of cCMVR, we analyzed 389 CMV seropositive patients who had received their first allo\u2010HCT. cCMVR was defined as the probability of the state where anti\u2010CMV drugs were administered for CMVR or CMV disease without relapse or death at any time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We compared two groups with or without letermovir prophylaxis (LTV and no\u2010LTV groups). The 1\u2010, 2\u2010, 3\u2010, and 6\u2010month cCMVR values were 0.0%, 0.0%, 2.9%, and 2.9% in the LTV group, and 7.1%, 31.9%, 11.0%, and 0.8% in the no\u2010LTV group. In the LTV group, cCMVR never exceeded 10%, while in the no\u2010LTV group, cCMVR peaked at approximately 2 months after allo\u2010HCT, and fewer than 5% of patients developed CMVR after 4 months post\u2010HCT. Next, in the no\u2010LTV group, we assessed cCMVR stratified according to the presence of risk factors for the simple cumulative incidence of CMVR, and this revealed that patients grafted from HLA\u2010mismatched related donors and those who received alemtuzumab for GVHD prophylaxis appeared to experience repeated episodes of CMVR, whereas the early difference in cCMVR according to pretransplant CMV\u2010IgG titer diminished over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>cCMVR could be a valuable indicator for visualizing recurrent CMV infection and illustrating differences in the time course of CMVR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tid.70337","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:45:25Z","timestamp":1791863125000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Novel Indicator of Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation: Current CMV Reactivation"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7844-9233","authenticated-orcid":false,"given":"Shunto","family":"Kawamura","sequence":"first","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-9315","authenticated-orcid":false,"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"},{"name":"Division of Emerging Medicine for Integrated Therapeutics (EMIT) Center for Molecular Medicine Jichi Medical University  Shimotsuke Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Honjo","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"},{"name":"Department of Hematology and Blood Transfusion Kochi Health Sciences Center  Kochi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1861-8434","authenticated-orcid":false,"given":"Junko","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-315X","authenticated-orcid":false,"given":"Yukiko","family":"Misaki","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6052-5815","authenticated-orcid":false,"given":"Kosuke","family":"Takano","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Hashino","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisuke","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nakata","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3982-2253","authenticated-orcid":false,"given":"Akari","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8790-844X","authenticated-orcid":false,"given":"Tomohiro","family":"Meno","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-6497","authenticated-orcid":false,"given":"Nozomu","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-5412","authenticated-orcid":false,"given":"Ayumi","family":"Gomyo","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-7913","authenticated-orcid":false,"given":"Masaharu","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-860X","authenticated-orcid":false,"given":"Machiko","family":"Kusuda","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8526","authenticated-orcid":false,"given":"Shun\u2010ichi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-3395","authenticated-orcid":false,"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"20","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early Cytomegalovirus Reactivation Remains Associated With Increased Transplant\u2010Related Mortality in the Current Era: A CIBMTR Analysis","volume":"127","author":"Teira P.","year":"2016","journal-title":"Blood"},{"issue":"25","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic\u2010Cell Transplantation","volume":"377","author":"Marty F. M.","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/bloodadvances.2023012175","article-title":"Late Cytomegalovirus Disease After Hematopoietic Cell Transplantation: Significance of Novel Transplantation Techniques","volume":"8","author":"Sadowska\u2010Klasa A.","year":"2024","journal-title":"Blood Advances"},{"issue":"2","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12185-022-03348-2","article-title":"Risk Factors for Late Cytomegalovirus Infection After Completing Letermovir Prophylaxis","volume":"116","author":"Mori Y.","year":"2022","journal-title":"International Journal of Hematology"},{"issue":"16","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/bloodadvances.2021004362","article-title":"Delayed\u2010Onset Cytomegalovirus Infection Is Frequent After Discontinuing Letermovir in Cord Blood Transplant Recipients","volume":"5","author":"Hill J. A.","year":"2021","journal-title":"Blood Advances"},{"issue":"1","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-023-05474-1","article-title":"Outcomes of Allogeneic Hematopoietic Cell Transplantation Under Letermovir Prophylaxis for Cytomegalovirus Infection","volume":"103","author":"Takenaka K.","year":"2024","journal-title":"Annals of Hematology"},{"issue":"4","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","article-title":"Efficacy of Prophylactic Letermovir for Cytomegalovirus Reactivation in Hematopoietic Cell Transplantation: A Multicenter Real\u2010World Data","volume":"56","author":"Mori Y.","year":"2021","journal-title":"Bone Marrow Transplantation"},{"issue":"5","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/bloodadvances.2023010735","article-title":"Differential Clinical Impact of Letermovir Prophylaxis According to Graft Sources: A KSGCT Multicenter Retrospective Analysis","volume":"8","author":"Toya T.","year":"2024","journal-title":"Blood Advances"},{"issue":"8","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV\u2010Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation","volume":"70","author":"Ljungman P.","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac687","article-title":"Real\u2010World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta\u2010Analysis of Observational Studies","volume":"10","author":"Vyas A.","year":"2023","journal-title":"Open Forum Infectious Diseases"},{"issue":"5","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/bloodadvances.2022008667","article-title":"The Promising Efficacy of a Risk\u2010Based Letermovir Use Strategy in CMV\u2010Positive Allogeneic Hematopoietic Cell Recipients","volume":"7","author":"Sourisseau M.","year":"2023","journal-title":"Blood Advances"},{"issue":"3","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.01.883","article-title":"Risk\u2010Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure after Allogeneic Hematopoietic Cell Transplantation","volume":"31","author":"Kawamura S.","year":"2025","journal-title":"Transplantation and Cellular Therapy"},{"issue":"25","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","article-title":"Impact of Donor CMV Status on Viral Infection and Reconstitution of Multifunction CMV\u2010Specific T Cells in CMV\u2010Positive Transplant Recipients","volume":"113","author":"Zhou W.","year":"2009","journal-title":"Blood"},{"issue":"8","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and Resistant Cytomegalovirus after Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era","volume":"73","author":"Sassine J.","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13715","article-title":"Association Between the Kinetics of Cytomegalovirus Reactivation in Terms of the Area Under the Curve of Cytomegalovirus Antigenemia and Non\u2010Relapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"23","author":"Takeshita J.","year":"2021","journal-title":"Transplant Infectious Disease"},{"issue":"3","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of Double\u2010Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation","volume":"66","author":"Hill J. A.","year":"2018","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","article-title":"Impact of GVHD Prophylaxis on CMV Reactivation and Disease After HLA\u2010Matched Peripheral Blood Stem Cell Transplantation","volume":"7","author":"Ueda Oshima M.","year":"2023","journal-title":"Blood Advances"},{"issue":"7","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.bbmt.2017.02.022","article-title":"Current Graft\u2010Versus\u2010Host Disease\u2013Free, Relapse\u2010Free Survival: A Dynamic Endpoint to Better Define Efficacy After Allogenic Transplant","volume":"23","author":"Solomon S. R.","year":"2017","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"7","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.bbmt.2018.02.004","article-title":"Refractory Graft\u2010Versus\u2010Host Disease\u2013Free, Relapse\u2010Free Survival as an Accurate and Easy\u2010to\u2010Calculate Endpoint to Assess the Long\u2010Term Transplant Success","volume":"24","author":"Kawamura K.","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"9","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.06.014","article-title":"Low\u2010Intensity Immunosuppressive Therapy for Chronic Graft\u2010Versus\u2010Host Disease","volume":"28","author":"Yoshimura K.","year":"2022","journal-title":"Transplantation and Cellular Therapy"},{"issue":"9","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.06.020","article-title":"Novel Indicators of Transplant Outcomes for PhALL: Current Molecular\u2010Relapse\u2010Free Survival","volume":"27","author":"Nakasone H.","year":"2021","journal-title":"Transplantation and Cellular Therapy"},{"issue":"6","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41409-020-01206-5","article-title":"Stopping Tyrosine Kinase Inhibitors Started After Allogeneic HCT in Patients With Philadelphia Chromosome\u2010Positive Leukemia","volume":"56","author":"Nakasone H.","year":"2021","journal-title":"Bone Marrow Transplantation"},{"issue":"3","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced\u2010Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt S.","year":"2009","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"3","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajh.21087","article-title":"Decreased Incidence of Acute Graft\u2010Versus\u2010Host Disease by Continuous Infusion of Cyclosporine With a Higher Target Blood Level","volume":"83","author":"Oshima K.","year":"2008","journal-title":"American Journal of Hematology"},{"issue":"4","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2009.213","article-title":"Target Blood Concentrations of CYA and Tacrolimus in Randomized Controlled Trials for the Prevention of Acute GVHD After Hematopoietic SCT","volume":"45","author":"Oshima K.","year":"2010","journal-title":"Bone Marrow Transplantation"},{"issue":"8","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.04.024","article-title":"Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus\u2010IgG Titer Before Allogeneic Hematopoietic Stem Cell Transplantation","volume":"27","author":"Kawamura S.","year":"2021","journal-title":"Transplantation and Cellular Therapy"},{"issue":"11","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.bbmt.2020.07.034","article-title":"Impact of Anti\u2010CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation From Alternative Donors on CMV Reactivation","volume":"26","author":"Arcuri L. J.","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"e_1_2_12_29_1","first-page":"p242","article-title":"Comparison of CLIA and EIA to Measure CMV\u2010IgG Titer for the Prediction of CMV Reactivation","volume":"44","author":"Kawamura S.","year":"2022","journal-title":"JSTCT 2022 Abstracts"},{"issue":"9","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073754","article-title":"Evaluation of the Validity of Preemptive Therapy Against Cytomegalovirus Disease Based on Antigenemia Assay With a Cutoff of 20 Positive Cells Per Two Slides","volume":"8","author":"Sakamoto K.","year":"2013","journal-title":"PLoS ONE"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2288-11-140","article-title":"Estimation of Current Cumulative Incidence of Leukaemia\u2010Free Patients and Current Leukaemia\u2010Free Survival in Chronic Myeloid Leukaemia in the Era of Modern Pharmacotherapy","volume":"11","author":"Pavl\u00edk T. S.","year":"2011","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the Freely Available Easy\u2010to\u2010Use Software \u2018EZR\u2019 for Medical Statistics","volume":"48","author":"Kanda Y.","year":"2013","journal-title":"Bone Marrow Transplantation"},{"issue":"3","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"289.e1","DOI":"10.1016\/j.cmi.2015.11.006","article-title":"Response to Antiviral Therapy in Haematopoietic Stem Cell Transplant Recipients With Cytomegalovirus (CMV) Reactivation According to the Donor CMV Serological Status","volume":"22","author":"Servais S.","year":"2016","journal-title":"Clinical Microbiology and Infection"},{"issue":"24","key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1182\/bloodadvances.2022008047","article-title":"Extended\u2010Duration Letermovir Prophylaxis for Cytomegalovirus Infection After Cord Blood Transplantation in Adults","volume":"6","author":"Politikos I.","year":"2022","journal-title":"Blood Advances"},{"issue":"2","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and Safety of Extended Duration Letermovir Prophylaxis in Recipients of Haematopoietic Stem\u2010Cell Transplantation at Risk of Cytomegalovirus Infection: A Multicentre, Randomised, Double\u2010Blind, Placebo\u2010Controlled, Phase 3 Trial","volume":"11","author":"Russo D.","year":"2024","journal-title":"Lancet Haematology"},{"issue":"1","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s42003-021-02709-7","article-title":"Features of Repertoire Diversity and Gene Expression in Human Cytotoxic T Cells Following Allogeneic Hematopoietic Cell Transplantation","volume":"4","author":"Nakasone H.","year":"2021","journal-title":"Communications Biology"},{"issue":"10","key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/s41409-021-01289-8","article-title":"Impact of the Combination of Donor Age and HLA Disparity on the Outcomes of Unrelated Bone Marrow Transplantation","volume":"56","author":"Seo S.","year":"2021","journal-title":"Bone Marrow Transplantation"},{"issue":"2","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The Effect of Donor Characteristics on Survival After Unrelated Donor Transplantation for Hematologic Malignancy","volume":"127","author":"Kollman C.","year":"2016","journal-title":"Blood"},{"issue":"9","key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1182\/bloodadvances.2024014408","article-title":"Impacts of Donor Age and HLA Mismatch on HCT Outcomes Differ According to the Donor CMV Serostatus in Unrelated Allo\u2010HCT","volume":"9","author":"Kawamura S.","year":"2025","journal-title":"Blood Advances"},{"issue":"9","key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) Cell\u2010Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study","volume":"71","author":"Chemaly R. F.","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"e_1_2_12_41_1","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13460","article-title":"Association of the Areas Over and Under the Lymphocyte Curve With Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"23","author":"Kimura S.\u2010I.","year":"2021","journal-title":"Transplant Infectious Disease"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.70337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:45:31Z","timestamp":1791863131000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.70337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":40,"alternative-id":["10.1111\/tid.70337"],"URL":"https:\/\/doi.org\/10.1111\/tid.70337","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"2026-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70337"}}